Jenapharm

Jenapharm is a pharmaceutical company and brand based in Jena, Germany. It was established on 1 January 1950 as the state-owned VEB Jenapharm in the Soviet occupation zone, drawing on pharmaceutical and microbiological capabilities that had developed in Jena after the Second World War. From its earliest years, the company concentrated on steroid hormones and related active pharmaceutical ingredients, an area in which East German producers faced severe supply constraints because commonly used steroid precursors could not reliably be imported from Western markets. To overcome those restrictions, Jenapharm developed an alternative synthesis route based initially on hyodeoxycholic acid obtained from hog bile. This process enabled the manufacture of steroid intermediates and medicines including progesterone, desoxycorticosterone acetate and several androgenic, estrogenic and corticosteroid compounds. During the 1950s and 1960s the company expanded its steroid portfolio, while research and industrial production remained closely linked. It later shifted toward total synthesis, adopting and further refining chemical routes that did not depend on scarce biological precursors. More than one hundred process improvements were reportedly patented, allowing production to grow substantially by the 1980s, although the transition also led Jenapharm to leave much of the corticosteroid market. Hormonal medicines became the company’s commercial center of gravity. Jenapharm produced Ovosiston, an early oral contraceptive containing chlormadinone acetate, from 1964. It subsequently launched Deposiston, a once-weekly oral contraceptive introduced in 1978, and Turisteron, an estrogen-related product used in the treatment of androgen-dependent prostate carcinoma. Collaboration with chemists from East German academic institutions also contributed to the development of dienogest. The ethinylestradiol/dienogest combination was first marketed as Certostat and later as Valette. After its German launch in 1990, Valette became one of the country’s leading oral contraceptives and was a major factor in the company’s commercial attractiveness after reunification. Before reunification, Jenapharm was the only supplier of hormonal contraceptives in East Germany and operated several production locations, including facilities associated with Jena, Erfurt, Naumburg and Magdeburg. At the end of the 1980s, it was among East Germany’s largest pharmaceutical producers, with approximately 1,700 employees and sales of about DM200 million, according to historical accounts. Following German reunification, the company was privatized in 1991 and sold to Gehe AG, a subsidiary of Franz Haniel & Cie. Schering AG later acquired full ownership, completing the acquisition in 2001. In 2004, Schering sold its generic therapeutics businesses to Dermapharm AG; Jenapharm’s marketing and distribution activities were subsequently organized as an independent subsidiary, while research and development were integrated into Schering laboratories. Jenapharm’s history is also inseparable from East Germany’s state-sponsored doping system. The company developed Oral Turinabol, an anabolic steroid that became one of the principal substances used in the program. It also produced epitestosterone propionate for a doping protocol intended to manipulate testosterone-to-epitestosterone ratios in athletes undergoing international testing. The long-term health effects experienced by former athletes led to lawsuits and public controversy in the 2000s. In 2005, Jenapharm contributed to a compensation fund established for affected former East German athletes. The company’s legacy therefore combines significant achievements in steroid chemistry and contraceptive development with serious ethical and legal questions concerning its involvement in state-directed sports doping.

Jenapharm’s origins lie in the pharmaceutical infrastructure created in Jena during the Soviet occupation of Germany. A predecessor research and production institution, the Schott-Zeiss Institute, had microbiological capabilities and produced penicillin shortly before the end of the Second World War. In the late 1940s, the institute also worked on vitamin D2 production in response to widespread rickets in the Soviet occupation zone. In 1949 it received a mandate to synthesize steroid hormones, particularly cortisone, and obtained permission to manufacture and market medicines. The public enterprise VEB Jenapharm was formally established on 1 January 1950, reportedly with roughly 600 employees. The company’s first major technical challenge was the lack of diosgenin and hecogenin, steroid precursors routinely used in Western production but unavailable to East German manufacturers. Jenapharm therefore developed a process beginning with hyodeoxycholic acid from hog bile. Through this route it produced pregnenolone and then progesterone and desoxycorticosterone acetate in the middle of the 1950s. Research director Alfred Schubert combined scientific and managerial responsibilities, helping connect laboratory work with industrial-scale manufacturing. From 1957 to 1962, Gerhard Langbein and other researchers expanded the range to include testosterone, 4-chlorotestosterone, cortexolone, cortisone, cortisol and prednisone. Jenapharm later sought plant-based and animal-derived alternatives to hog bile, including experiments involving Solanum auriculatum, Cuban sugar-cane wax and cholesterol from animal spinal cords. These approaches did not prove economical at industrial scale. The company consequently moved toward total steroid synthesis, drawing on the synthesis scheme associated with Igor Torgov and adapting it through extensive process development. Output initially remained modest, but improvements eventually increased annual production to several tons by the 1980s. This shift strengthened Jenapharm’s position in anabolic steroids, estrogens and progestins, while reducing or ending its participation in some corticosteroid markets. The company’s commercial product development was relatively limited in its early decades, but its hormonal portfolio became strategically important. Chlormadinone acetate was marketed as the oral contraceptive Ovosiston from 1964. Academic collaboration in the German Democratic Republic contributed to the development of strongly active estrogen products, including Deposiston, introduced in 1978 as a once-weekly oral contraceptive, and Turisteron, used for androgen-dependent prostate carcinoma. In 1975, chemist Kurt Ponsold synthesized the progestin dienogest in cooperation with Jenapharm. Its combination with ethinylestradiol was first sold as Certostat and later as Valette. Valette’s strong performance in unified Germany made Jenapharm an important competitor in the national oral-contraceptive market and helped attract Schering’s interest. In the late 1980s, Jenapharm had production sites in Jena, Erfurt, Naumburg and Magdeburg. Historical accounts describe it as one of East Germany’s three largest pharmaceutical manufacturers, with around 1,700 employees and sales of approximately DM200 million; hormones represented about half of sales. In 1991, the company was privatized and sold to Gehe AG after Schering’s initial bid did not succeed. Schering later acquired all Jenapharm stock, with full ownership reported by 2001. The company’s post-reunification history was shaped by restructuring. In 2004, Schering sold its generic therapeutics businesses to Dermapharm AG. In 2005, Jenapharm’s marketing and distribution were reorganized as an independent subsidiary, while research and development was integrated into Schering’s own laboratories. Jenapharm subsequently continued as a pharmaceutical brand within the Dermapharm corporate context. A major and damaging part of the historical record concerns the East German state-sponsored doping system. Jenapharm developed 4-chlorodehydromethyltestosterone, marketed as Oral Turinabol, which became widely used in the doping of athletes. The company also manufactured epitestosterone propionate, a substance without a substantial ordinary commercial application that was used in combination with testosterone to influence doping-test ratios. Athletes, including minors and women, experienced serious long-term effects such as virilization, reproductive complications, liver damage and other medical problems. In 2005, former athletes brought claims against Jenapharm and argued that the company had supplied substances for doping and failed to disclose relevant risks. The dispute ended with the establishment of a compensation fund involving the German Olympic Sports Federation and a financial contribution from Jenapharm, while funds were reserved for later claims.

• 2005

  Doping-related compensation arrangement

  [1]Jenapharmen.wikipedia.org

  Former East German athletes pursued claims over the health effects of doping substances, leading to a compensation fund to which Jenapharm contributed.

• 2004

  Dermapharm acquires Schering generic therapeutics businesses

  [1]Jenapharmen.wikipedia.org

  Dermapharm AG acquired Schering’s generic therapeutics activities, creating the ownership transition associated with Jenapharm’s later corporate structure.

• 2001

  Schering obtains full ownership

  [1]Jenapharmen.wikipedia.org

  Schering completed its acquisition of all Jenapharm stock.

• 1991

  Privatization

  [1]Jenapharmen.wikipedia.org

  Jenapharm was privatized after German reunification and sold to Gehe AG.

• 1990

  Valette enters the German market

  [1]Jenapharmen.wikipedia.org

  The ethinylestradiol/dienogest contraceptive combination was marketed as Valette and soon became a leading oral contraceptive in Germany.

• 1978

  Deposiston launches

  [1]Jenapharmen.wikipedia.org

  The company introduced Deposiston, described as the first once-weekly oral contraceptive, based on ethinylestradiol sulfonate and norethisterone acetate.

• 1964

  Ovosiston is introduced

  [1]Jenapharmen.wikipedia.org

  Jenapharm marketed chlormadinone acetate as Ovosiston, its first oral contraceptive product.

• 1954

  Hog-bile steroid synthesis reaches production

  [1]Jenapharmen.wikipedia.org

  Jenapharm developed an alternative steroid-production route from hyodeoxycholic acid obtained from hog bile, enabling production of key steroid intermediates.

• 1950

  VEB Jenapharm is established

  [1]Jenapharmen.wikipedia.org

  The state-owned pharmaceutical enterprise VEB Jenapharm was founded in Jena on 1 January.

• 1949

  Steroid-hormone mandate and pharmaceutical authorization

  [1]Jenapharmen.wikipedia.org

  The Jena research and production institute was tasked with steroid-hormone synthesis and received authorization to manufacture and market pharmaceuticals.

A German pharmaceutical brand with historical expertise in steroid chemistry, hormonal medicines and contraceptive products, now associated with Dermapharm’s pharmaceutical portfolio.

• Oral contraceptive · 1990

  Valette

  Valette combines ethinylestradiol with the progestin dienogest. Developed from cooperation involving Jenapharm and East German chemists, it was initially marketed under the name Certostat and later relaunched as Valette. Introduced in Germany around 1990, it achieved strong sales and became one of the country’s best-selling oral contraceptives during the 1990s.

• Oral contraceptive · 1964

  Ovosiston

  Ovosiston was Jenapharm’s oral contraceptive based on chlormadinone acetate. Introduced in 1964, it represented an early commercial application of the company’s steroid-production expertise and was produced using the company’s then distinctive hog-bile-derived synthesis route.

• Oral contraceptive · 1978

  Deposiston

  Deposiston was introduced in 1978 as a once-weekly oral contraceptive. Its formulation used ethinylestradiol sulfonate together with norethisterone acetate, reflecting Jenapharm’s work on potent estrogen and progestin compounds developed through cooperation with East German academic researchers.

• Hormonal oncology medicine

  Turisteron

  Turisteron contained ethinylestradiol sulfonate and was developed as a hormonally active medicine for androgen-dependent carcinoma of the prostate. It emerged from Jenapharm’s collaborative research program on potent estrogens and illustrates the company’s broader focus on steroid medicines beyond contraception.

• Anabolic steroid

  Oral Turinabol

  Oral Turinabol was the trade name for 4-chlorodehydromethyltestosterone, an anabolic steroid developed by Jenapharm. Although it was a pharmaceutical product, it became closely associated with East Germany’s state-sponsored doping program, where it was administered to athletes, including minors. Its legacy is central to the company’s later legal and ethical controversy.

• 2005

  East German state-sponsored doping litigation

  Former East German athletes brought claims against Jenapharm over long-term medical consequences associated with anabolic steroids and other substances used in the state doping system. The claims alleged that Jenapharm had supplied doping-related substances and had not adequately disclosed their risks. A settlement framework created a compensation fund, with Jenapharm contributing to the fund and additional money reserved for future claims.

  Source

Read more

• 2005

  Participate in doping-related compensation fundOther

  Background

  Former athletes alleged that Jenapharm’s anabolic steroids and other substances had contributed to serious long-term health problems within East Germany’s state-sponsored doping system.

  Action taken

  Jenapharm contributed to a compensation fund established for affected former athletes.

  Aftermath

  The arrangement provided compensation while leaving the doping controversy as a defining ethical and reputational issue in Jenapharm’s history.

  Compensation fund. $4.1 million (2005)

  Source

• 1991

  Privatize and sell Jenapharm to GeheM&A

  Background

  German reunification required the transformation of the former East German state enterprise into a privately owned company.

  Action taken

  Jenapharm was privatized and sold to Gehe AG, a subsidiary of Franz Haniel & Cie.

  Aftermath

  Ownership later moved to Schering, which acquired full ownership by 2001.

  Source

• 1990

  Commercialize ValetteProduct launch

  Background

  Jenapharm had access to the dienogest compound developed through cooperation with Kurt Ponsold and other East German researchers.

  Action taken

  The company marketed the ethinylestradiol/dienogest combination under the name Valette after its earlier Certostat branding.

  Aftermath

  Valette became a major German oral contraceptive and helped make Jenapharm an attractive acquisition target for Schering.

  Annual sales. DM40 million (1996)

  • Schering AG — Schering pursued and ultimately acquired Jenapharm, with Valette’s market performance identified as an important attraction.

  Source

• 1978

  Launch DeposistonProduct launch

  Background

  Research collaboration in East Germany produced highly active estrogen compounds with potential for longer dosing intervals.

  Action taken

  Jenapharm launched Deposiston, a once-weekly oral contraceptive containing ethinylestradiol sulfonate and norethisterone acetate.

  Aftermath

  The product demonstrated Jenapharm’s ability to turn domestic hormone research into differentiated contraceptive products.

  Source

• 1964

  Launch OvosistonProduct launch

  Background

  Jenapharm had developed steroid-production capabilities and was the principal supplier of hormonal contraceptives in East Germany.

  Action taken

  The company introduced chlormadinone acetate as the oral contraceptive Ovosiston.

  Aftermath

  Ovosiston established a commercial foundation for Jenapharm’s later focus on hormonal contraception.

  Source

• 1950

  Build a steroid-centered pharmaceutical businessStrategy

  Background

  East Germany lacked reliable access to Western steroid precursors, while the government sought domestic pharmaceutical production and medicines for public-health needs.

  Action taken

  Jenapharm developed local steroid chemistry, initially using hyodeoxycholic acid from hog bile and later moving toward total synthesis.

  Aftermath

  The strategy made Jenapharm a significant East German producer of steroid hormones and related medicines, although it eventually reduced the company’s role in corticosteroids.

  Source

1. 1Jenapharmen.wikipedia.org
2. 2Jenapharm official websitejenapharm.de